Peter Wrighton Smith News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AUSTIN, Texas and OXFORD, U.K., Dec. 7, 2021 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a developer of novel HLA based transplant diagnostics, and Oxford Immunotec, Ltd. (OI), a global diagnostics company part of PerkinElmer Inc., today announce an exclusive sublicense agreement in which PTS will obtain exclusive commercial rights to issued patents protecting a novel assay originally developed by Dr. Oriol Bestard, M.D., Ph.D. - News from Pure Transplant Solutions LLC, issued by Send2Press Newswire

ENewsChannels NEWS: -- Pure Transplant Solutions, LLC (PTS), a developer of novel HLA based transplant diagnostics, and Oxford Immunotec, Ltd. (OI), a global diagnostics company part of PerkinElmer Inc., today announce an exclusive sublicense agreement in which PTS will obtain exclusive commercial rights to issued patents protecting a novel assay originally developed by Dr. Oriol Bestard, M.D., Ph.D. :: News from eNewsChannels

(2) OXFORD, United Kingdom and MARLBOROUGH, Mass., April 29, 2021(NYSE: PKI), today announced that its T-SPOT Discovery SARS-CoV-2 kit will be used for T cell testing in the DIRECT study. Oxford Immunotec is collaborating with researchers at the University of Leicester on DIRECT (Determining the Immune Response in Ethnic minority healthcare workers to COVID-19 infection). The study, funded through the National Core Studies group, is actively recruiting healthcare workers in Leicester for detailed analysis of their immune response to infection and / or vaccination (including T cells). This ana...

Oxford Immunotec Global Limite Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test Used in DIRECT Study to Investigate the T Cell Response and COVID Vaccination in Ethnic Minority Groups Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test Used in DIRECT Study to Investigate the T Cell Response and COVID Vaccination in Ethnic Minority Groups OXFORD, United Kingdom and MARLBOROUGH, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec a global, high-growth diagnostics company part of PerkinElmer (NYSE: PKI), today announced that its T-SPOT ® Discovery SARS-CoV-2 kit will be used fo...

Oxford Immunotec’s COVID-19 test to be used in ‘mix and match’ UK vaccine trial 28th April 2021 Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 test kit is set to be used for T cell testing in the UK Com-Cov trial, which is evaluating different combinations of approved COVID-19 vaccines. The Com-Cov study will be the first in the world to evaluate the effects of using different vaccines for the first and second dose within a two-dose vaccination regimen. It will be run by the National Immunisation Schedule Evaluation Consortium (NISEC) across eight National Institute for Health Researc...